233 related articles for article (PubMed ID: 30254376)
1. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.
Fattore L; Ruggiero CF; Pisanu ME; Liguoro D; Cerri A; Costantini S; Capone F; Acunzo M; Romano G; Nigita G; Mallardo D; Ragone C; Carriero MV; Budillon A; Botti G; Ascierto PA; Mancini R; Ciliberto G
Cell Death Differ; 2019 Jul; 26(7):1267-1282. PubMed ID: 30254376
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
3. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J
Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
[TBL] [Abstract][Full Text] [Related]
5. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
Tian Y; Guo W
Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
[TBL] [Abstract][Full Text] [Related]
7.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
8. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
9. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V
Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
11. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
Nguyen MT; Lin CH; Liu SM; Miyashita A; Ihn H; Lin H; Ng CH; Tsai JC; Chen MH; Tsai MS; Lin IY; Liu SC; Li LY; Fukushima S; Lu J; Ma N
Neoplasia; 2020 Dec; 22(12):789-799. PubMed ID: 33142243
[TBL] [Abstract][Full Text] [Related]
12. Targeting CDC7 sensitizes resistance melanoma cells to BRAF
Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY
Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454
[TBL] [Abstract][Full Text] [Related]
13. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
14. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
15. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
18. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
19. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.
Fattore L; Cafaro G; Di Martile M; Campani V; Sacconi A; Liguoro D; Marra E; Bruschini S; Stoppoloni D; Cirombella R; De Nicola F; Pallocca M; Ruggiero CF; Castaldo V; Catizone A; Del Bufalo D; Viglietto G; Vecchione A; Blandino G; Aurisicchio L; Fanciulli M; Ascierto PA; De Rosa G; Mancini R; Ciliberto G
Oncogene; 2023 Jan; 42(4):293-307. PubMed ID: 36418472
[TBL] [Abstract][Full Text] [Related]
20. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
Grzywa TM; Klicka K; Paskal W; Dudkiewicz J; Wejman J; Pyzlak M; Włodarski PK
PLoS One; 2020; 15(6):e0234707. PubMed ID: 32555626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
